Article Text

Download PDFPDF
Withdrawal of the British Society of Gastroenterology IBD risk grid for COVID-19 severity
  1. Charlie W Lees1,
  2. Tariq Ahmad2,
  3. Christopher Andrew Lamb3,4,
  4. Nick Powell5,
  5. Shahida Din6,
  6. Rachel Cooney7,
  7. Nicholas A Kennedy8,9,
  8. Rachel Ainley10,
  9. Ruth Wakeman10,
  10. Christian Philipp Selinger11
  1. 1 Gastrointestinal Unit, Western General Hospital, Edinburgh, Scotland, UK
  2. 2 IBD Research Group, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK
  3. 3 Translational & Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK
  4. 4 Gastroenterology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
  5. 5 Imperial College London, London, UK
  6. 6 Gastroenterology, Western General Hospital, Edinburgh, UK
  7. 7 Queen Elizabeth Hospital Birmingham, Birmingham, UK
  8. 8 Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, Devon, UK
  9. 9 University of Exeter, Exeter, Devon, UK
  10. 10 Crohn's and Colitis UK, Saint Albans, Hertfordshire, UK
  11. 11 Gastroenterology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
  1. Correspondence to Dr Christian Philipp Selinger, Gastroenterology, Leeds Teaching Hospitals NHS Trust, Leeds, UK; christian.selinger{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

At the start of the SARS-CoV-2 pandemic, we and others produced guidance for people living with IBD and their clinical teams on behalf of the British Society of Gastroenterology.1 This included publication of a risk grid based on key variables that were believed to increase the risk of adverse COVID-19 outcomes. The grid has been widely adopted providing a useful framework for patients, clinicians and policymakers but is now no longer relevant and should not be used.

The risk grid was the basis for categorisation into clinically vulnerable and extremely clinically vulnerable grouping informing those who should follow ‘shielding’ recommendations. It subsequently informed prioritisation for vaccination against SARS-CoV-2 and more recently use of antivirals and monoclonal antibody therapies directed against SARS-C0V-2 . We developed the grid in April 2020 based on early information about the …

View Full Text


  • Twitter @charlie_lees, @DrChrisLamb

  • Contributors All authors developed the recommendation. CWS drafted the manuscript. All authors critically reviewed the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.